Policy and Design Considerations for Most-Favored-Nation Drug Pricing

This Viewpoint discusses most-favored-nation drug pricing and how to strengthen this type of drug pricing in Medicare.

Corresponding Author: Olivier J. Wouters, PhD, Department of Health Services, Policy, and Practice, Brown University School of Public Health, 121 S Main St, Providence, RI 02903 (olivier_wouters@brown.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.